ARIAD PHARMACEUTICALS INC's ticker is ARIA and the CUSIP is 04033A100. A total of 198 filers reported holding ARIAD PHARMACEUTICALS INC in Q2 2013. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $4,169,000 | -10.2% | 335,200 | -1.2% | 0.05% | -21.7% |
| Q3 2016 | $4,645,000 | +165.0% | 339,300 | +42.9% | 0.07% | +155.6% |
| Q2 2016 | $1,753,000 | +1238.2% | 237,400 | +13758.7% | 0.03% | +575.0% |
| Q1 2016 | $131,000 | -61.6% | 1,713 | -85.1% | 0.00% | -42.9% |
| Q4 2015 | $341,000 | -60.8% | 11,490 | +6.5% | 0.01% | -66.7% |
| Q3 2015 | $869,000 | +97.9% | 10,787 | -0.5% | 0.02% | +110.0% |
| Q2 2015 | $439,000 | +1.2% | 10,839 | +8.1% | 0.01% | +11.1% |
| Q1 2015 | $434,000 | -60.3% | 10,023 | -42.8% | 0.01% | -57.1% |
| Q4 2014 | $1,094,000 | +15.8% | 17,535 | +38.0% | 0.02% | +5.0% |
| Q3 2014 | $945,000 | +115.3% | 12,709 | +103.2% | 0.02% | +100.0% |
| Q2 2014 | $439,000 | -22.2% | 6,254 | -87.5% | 0.01% | -9.1% |
| Q1 2014 | $564,000 | +169.9% | 50,050 | +88.3% | 0.01% | +120.0% |
| Q4 2013 | $209,000 | +850.0% | 26,582 | +2170.0% | 0.01% | – |
| Q3 2013 | $22,000 | 0.0% | 1,171 | 0.0% | 0.00% | -100.0% |
| Q2 2013 | $22,000 | – | 1,171 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 12,850,000 | $69,390,000 | 26.80% |
| Opaleye Management Inc. | 1,500,000 | $8,100,000,000 | 6.31% |
| Camber Capital Management LP | 6,000,000 | $32,400,000 | 3.04% |
| Ghost Tree Capital, LLC | 700,000 | $3,780,000 | 2.05% |
| Granite Point Capital Management, L.P. | 700,000 | $3,780,000 | 1.88% |
| Duquesne Family Office | 1,645,000 | $8,883,000 | 1.09% |
| Geduld E E | 272,200 | $1,470,000 | 1.04% |
| Elk Creek Partners, LLC | 659,232 | $3,560,000 | 0.93% |
| Palo Alto Investors LP | 2,231,717 | $12,051,000 | 0.90% |
| HighVista Strategies LLC | 1,200,000 | $6,480,000 | 0.87% |